[Research progress on early biomarkers of Alzheimer's disease].
Researchers
W J Cai, Y J Xie, X R Liu, X Y Zhao, R Q Li
Abstract
As the global population continues to age, Alzheimer's disease (AD) has become a serious public health issue. Compared to traditional diagnostic methods, blood biomarkers offer new avenues for early AD screening due to their advantages, such as low invasiveness and high throughput. In 2024, the National Institute on Aging-Alzheimer's Association (NIA-AA) updated its ATN biomarker research framework, in which A, T, and N denote β-amyloid, tau, and neurodegeneration (hereafter the ATN framework), formally establishing the diagnostic status of blood biomarkers and proposing Core 1 and Core 2 biomarkers for disease diagnosis and pathological staging; and atypical biomarkers, such as those related to neurodegeneration, inflammation, vascular damage, and comorbid proteins, to reflect mixed pathological states. Although these markers show substantial potential for early AD screening, their clinical translation is still limited by insufficient standardisation across assay platforms and by assay interference. This review summarises recent advances in early AD biomarkers and outlines the challenges and prospects for their translation. 随着全球人口老龄化加剧,阿尔茨海默病(AD)已成为一个严重的公共卫生问题。相较于传统检测方法,血液生物标志物因低侵入性、高通量等优势,为AD早期筛查提供新途径。2024年美国国立老化研究所-阿尔茨海默病协会更新ATN(β-淀粉样蛋白/tau蛋白/神经变性)生物学标志物研究框架,正式确立血液标志物的诊断地位,提出Core1、Core2核心生物标志物,用于疾病诊断与病理分期;神经变性、炎症、血管损伤和共病蛋白等非典型生物标志物,用于反映混合病理状态。这些标志物虽显现巨大的AD早期筛查潜力,但在转化中仍面临不同检测平台间标准化不足、检测干扰等问题。本文系统梳理AD早期生物标志物的研究进展,并分析其面临的挑战及前景。.Source: PubMed (PMID: 43035305)View Original on PubMed